Bristol Myers Squibb Co. said Thursday it will restate earnings downward for parts of 2024 and 2023 while revising this year's earnings upward because of its massive inventory backlog imbroglio that spurred two government investigations.
Bristol Myers to restate earnings as third quarter profits plunge.